Wall Street brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce earnings of ($0.57) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.56). Syros Pharmaceuticals reported earnings per share of ($0.47) during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.3%. The company is expected to issue its next earnings results on Monday, March 19th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($2.12) per share for the current year, with EPS estimates ranging from ($2.14) to ($2.10). For the next financial year, analysts forecast that the firm will report earnings of ($2.60) per share, with EPS estimates ranging from ($3.69) to ($2.00). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.53).
In other news, Director Srinivas Akkaraju purchased 109,774 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was bought at an average cost of $9.03 per share, with a total value of $991,259.22. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jeremy P. Springhorn purchased 15,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were purchased at an average cost of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 334,198 shares of company stock valued at $3,127,458. Company insiders own 33.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Advisers LP purchased a new stake in shares of Syros Pharmaceuticals during the 4th quarter worth about $105,000. Adalta Capital Management LLC purchased a new stake in shares of Syros Pharmaceuticals during the 4th quarter worth about $111,000. Nationwide Fund Advisors raised its stake in shares of Syros Pharmaceuticals by 249.8% during the 2nd quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Syros Pharmaceuticals during the 3rd quarter worth about $133,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Syros Pharmaceuticals during the 3rd quarter worth about $149,000. 48.41% of the stock is owned by institutional investors.
Syros Pharmaceuticals (NASDAQ:SYRS) opened at $10.24 on Thursday. The firm has a market capitalization of $334.43, a price-to-earnings ratio of -5.09 and a beta of -2.36. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.38.
WARNING: “Syros Pharmaceuticals Inc (SYRS) Expected to Announce Earnings of -$0.57 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/syros-pharmaceuticals-inc-syrs-expected-to-announce-earnings-of-0-57-per-share.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.